(Reuters) – Anthera Pharmaceuticals Inc stated on Tuesday that its drug to deal with sure cystic fibrosis sufferers failed a late-stage research, sending the corporate’s shares tumbling almost 70 % in after-hours buying and selling.
The newest setback for Anthera comes simply over a month after the corporate stated an experimental drug to deal with lupus had additionally failed in a late-stage research.
Cystic fibrosis is an inherited genetic situation that primarily impacts the digestive and reproductive methods and the lungs. The drug, sollpura, was being examined on sufferers whose cystic fibrosis had led to exocrine pancreatic insufficiency (EPI), an enzyme deficiency that results in improper digestion.
Sollpura was being examined on its capability to assist sufferers take up fats in a non-inferiority trial, the place a brand new remedy has to point out it isn’t clinically worse than an lively remedy close to specified targets.
Sollpura failed on this rely when its efficiency was in contrast with Janssen Pharmaceuticals’ pancreaze, Anthera stated.
However, Anthera stated sollpura’s means to soak up protein was not clinically worse and that, based mostly on this discovering, it will begin a brand new research within the first quarter of 2017.
Anthera’s shares have been down about 67 % at 69 cents in buying and selling after the bell on Tuesday. Up to the day’s shut, that they had misplaced 57 % this yr.
(Reporting by Dipika Jain in Bengaluru; Editing by Savio D’Souza)